Innoviva Acquires Entasis Therapeutics

Esperion Therapeutics to Acquire Corstasis Therapeutics

March 5, 2026

Biotechnology

Esperion Therapeutics announced it has entered into a definitive agreement to acquire Corstasis Therapeutics for an upfront cash payment of $75 million, with potential milestone payments of up to $180 million. The deal is expected to add Enbumyst (bumetanide nasal spray) to Esperion’s cardiovascular portfolio, leveraging its commercial infrastructure to expand its cardiovascular franchise.

Innoviva Acquires La Jolla Pharmaceutical Company

July 11, 2022

Pharmaceuticals

Innoviva entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company for $6.23 per share in cash (including a tender offer), representing an implied enterprise value of about $149 million. The acquisition adds GIAPREZA and XERAVA to Innoviva’s infectious disease and hospital portfolio and was completed in August 2022, with La Jolla becoming a wholly owned subsidiary and delisted from Nasdaq.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics

August 31, 2020

Biotechnology

Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.

Altavant Sciences Acquires Onspira Therapeutics

January 8, 2020

Biotechnology

Altavant Sciences has acquired Onspira Therapeutics, adding OSP-101 — an inhaled interleukin-1 receptor antagonist with orphan drug designation for bronchiolitis obliterans syndrome (BOS) — to its rare respiratory disease pipeline. The deal closed with upfront and milestone payments to Onspira's shareholders and expands Altavant's capabilities in pulmonary transplant-related therapeutics.